Literature DB >> 8983127

Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues.

J C Lormeau1, J P Herault, C Gaich, T Barzu, T G van Dinther, A Visser, J M Herbert.   

Abstract

The anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 was assayed by a chromogenic method at pH 8.4 and pH 7.35, comparatively to the 4th International Heparin Standard (IHS) or to the Ist International Low Molecular Weight Heparin Standard (LMWHS). At pH 8.4, SR 90107A/ORG 31540 was found to have a specific anti-factor Xa activity of 639 +/- 14 and 659 +/- 19 IU/mg (mean +/- sem, n = 6) when assayed in comparison with the 4th ISH and the Ist LMWHS respectively. At pH 7.35, the corresponding figures were 864 +/- 6 and 1160 +/- 51 IU/mg (mean +/- sem, n = 6) respectively. The dissociation constants of the ATIII-pentasaccharide complex formed by SR 90107A/ORG 31540 and by two close analogues: SR 80327A and SR 80027A in the presence of purified human ATIII were found to be 41 +/- 8, 96 +/- 1 and 3 +/- 1.4 nM (mean +/- sem, n = 3) respectively. For the three compounds, the pseudo-first order molar catalytic constants for factor Xa inactivation by the ATIII-pentasaccharide complex were shown to be statistically comparable, in the range of 7-8 x 10(7) min-1 per mole. It is concluded that the differences in specific anti-factor Xa activities between SR 90107A/ORG 31540 and its synthetic chemical analogues can be attributed to variations of the dissociation constants whereas the catalytic constants for factor Xa inactivation remain unchanged.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8983127     DOI: 10.1016/s0049-3848(96)00223-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.

Authors:  J Herbert; F Bono; J Herault; C Avril; F Dol; A Mares; P Schaeffer
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

2.  Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.

Authors:  Carolyne Lieu; Juan Shi; François Donat; Robert Van Horn; William Brian; John Newton; Leon Delbressine; Ria Vos
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins.

Authors:  Francis Paolucci; Marie-Christine Claviés; François Donat; José Necciari
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers.

Authors:  Céline Ollier; Richard A Faaij; Alix Santoni; Thierry Duvauchelle; Paul M M van Haard; Rik C Schoemaker; Adam F Cohen; Rik de Greef; Jacobus Burggraaf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Fondaparinux sodium.

Authors:  Susan J Keam; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.

Authors:  Neil A Reynolds; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Carbohydrate-based drugs launched during 2000-2021.

Authors:  Xin Cao; Xiaojing Du; Heng Jiao; Quanlin An; Ruoxue Chen; Pengfei Fang; Jing Wang; Biao Yu
Journal:  Acta Pharm Sin B       Date:  2022-05-23       Impact factor: 14.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.